Crovalimab
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0) . Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His) . Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP) . Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research[1][2].
Product Specifications
CAS Number
1917321-26-6
Product Name Alternative
SKY59; RO7112689; RG-6107
UNSPSC
12352203
Target
Complement System
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/crovalimab.html
Purity
99.95
Solubility
10 mM in DMSO
Smiles
[Crovalimab]
Molecular Weight
(145.28 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD45 / LCA (135-4C5), CF594 conjugate, 0.1mg/mL
Universal SYBR Green qPCR Master Mix
![CD45 (PTPRC) (CD45RO) Mouse Monoclonal Antibody [Clone ID: SPM125]](https://cdn.genprice.uk/products/937/68dd189e061270361e8fd793/imageurl/am50158pu-s.webp)